Kalaris Therapeutics reports positive Phase 1a data for TH103 in nAMD; accelerates development

Kalaris Therapeutics, Inc.

Mean 10-letter BCVA gain and 129 µm CST improvement at Month 1 across all dose levels (0.5–2.5 mg).
Mean ~95% reduction in central subfield intraretinal fluid; no dose-limiting toxicities or TH103-related serious AEs.
Two transient IOI cases at 2.5 mg resolved with manufacturing process change; zero new IOI in 6 subsequent subjects.
31% of patients (4/13) required no additional anti-VEGF treatment during the 6-month follow-up after a single injection.
Plasma Cmax 27–51-fold lower vs. leading anti-VEGF agents; Phase 1b/2 enrollment ongoing, preliminary data expected 2H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.